Loading
Head and Neck Cancer · Journal article
The Japanese Dental Science Review · June 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
This systematic review consolidates evidence from 33 preclinical and correlative studies showing that metadherin (MTDH) is consistently overexpressed in head and neck cancer and correlates with advanced clinicopathological features, poor prognosis, and promotion of migration, invasion, EMT, and chemoresistance through activation of NF-κB, PI3K/Akt, Wnt, and MAPK pathways. The review identifies MTDH as a potential prognostic biomarker and therapeutic target but provides no data from clinical trials testing MTDH-directed interventions or demonstrating clinical benefit.
Systematic review. Patients with HNC or experimental HNC models (cell lines and animal models); comparisons included empty vector controls, scramble controls, or normal/MTDH-low tissues. Intervention: MTDH expression alteration including overexpression, knockdown, or knockout. Compared with: Empty vector-transfected cells, scramble controls, or normal/MTDH-low tissues.
MTDH was consistently overexpressed across HNC subtypes and associated with advanced clinicopathological features and poor prognosis Elevated MTDH promotes migration, invasion, metastasis, epithelial-mesenchymal transition, proliferation, angiogenesis, and chemoresistance in functional studies MTDH activates NF-κB, PI3K/Akt, Wnt, and MAPK pathways and is post-transcriptionally regulated by nine miRNAs
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
MTDH shows promise as a prognostic biomarker correlating with poor outcomes in HNC, but clinicians should recognize that this evidence is derived entirely from preclinical and correlative studies without clinical trials demonstrating that MTDH inhibition improves patient outcomes. Current therapeutic applications remain investigational.
This is a systematic review of 33 observational and experimental studies with no randomized controlled trials or clinical outcome data, synthesizing preclinical and correlative evidence that MTDH is overexpressed in HNC and promotes oncogenic functions, but lacking direct evidence of clinical benefit from MTDH-directed intervention.
As stated by the source record.
Quoted from the source exactly as published.
MTDH shows promise as a prognostic biomarker correlating with poor outcomes in HNC, but clinicians should recognize that this evidence is derived entirely from preclinical and correlative studies without clinical trials demonstrating that MTDH inhibition improves patient outcomes. Current therapeutic applications remain investigational.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Purpose. Metadherin (MTDH) is frequently overexpressed across human malignancies, yet its roles in head and neck cancer (HNC) remain incompletely characterized. This systematic review evaluates the biological functions, molecular mechanisms, and clinical relevance of MTDH in HNC.Methods. A systematic literature search was conducted across four electronic databases (PubMed, Embase, Scopus, and Web of Science) in accordance with PRISMA 2020 guidelines.Results. Thirty-three studies met inclusion criteria. MTDH was consistently overexpressed across HNC subtypes and associated with advanced clinicopathological features and poor prognosis. Functional studies demonstrated that elevated MTDH promotes migration, invasion, metastasis, epithelial-mesenchymal transition (EMT), proliferation, angiogenesis, and chemoresistance. Mechanistically, MTDH activates NF-κB, PI3K/Akt, Wnt, and MAPK pathways and is post-transcriptionally regulated by nine miRNAs, with HNC-specific features including a CCL18-driven macrophage paracrine axis, MMP1-selective NF-κB effector activity, and a potential association with invasion front architecture as reflected by Worst Pattern of Invasion (WPOI). Clinically, MTDH modulates chemoresistance, ferroptosis-mediated radiosensitivity, and immune checkpoint expression.Conclusion. This systematic review identifies MTDH as a multifaceted oncoprotein that plays a central role in HNC progression, metastasis, and therapeutic response, highlighting its potential as a prognostic biomarker and therapeutic target.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.